Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) common stock pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering (“IPO”) on or around September 15, 2023.
Neumora is a clinical-stage biopharmaceutical company that focuses on the development of treatments for depression and other mental illnesses. Neumora’s flagship drug candidate navacaprant (“Nava”) is an oral kappa opioid receptor antagonist for the treatment of mild to moderate major depressive disorder (“MDD”). Neumora acquired Nava, along with other therapeutic candidates, through its 2020 acquisition of BlackThorn Therapeutics, Inc., a biotech startup.
The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) for Neumora to later justify conducting its phase three program, Neumora amended Nava’s phase two trial inclusion criteria of patients with mild to moderate MDD to include a patient population with moderate to severe MDD; (2) to that same end, Neumora added a prespecified analysis to the phase two statistical analysis plan, focusing on patients with moderate to severe MDD; (3) Nava’s phase two trial failed to achieve statistical significance compared to the placebo at eight weeks for the moderate to severe MDD patient population and lacked adequate data to be able to accurately predict the results of the first study in the phase three program; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On March 11, 2026, Defendants filed a Motion to Dismiss the Amended Complaint. The Motion is currently being briefed by the parties. This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.